ATNX:NSD-Athenex, Inc (USD)

COMMON STOCK | Drug Manufacturers—Specialty & Generic | NSD

Last Closing Price

USD 12.52

Change

-0.61 (-4.65)%

Market Cap

USD 1.20B

Volume

0.68M

Average Target Price

USD 28.00 (+123.64%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions in North America and Asia. It operates in three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oraxol, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignances and gastric cancer; and Oratecan, an oral dosage form of irinotecan that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer. Its Orascovery product candidates also comprise Oradoxel, an oral dosage form of docetaxel, which is in Phase I clinical study for breast, lung, prostate, gastric, and head and neck cancers; Oratopo, an oral dosage form of topotecan that is Phase I clinical trial to treat lung, ovarian, and cervical cancer; and oral eribulin, an intravenous anticancer drug to treat certain patients with breast cancer and advanced liposarcoma. In addition, the company offers Src Kinase product candidates comprising KX2-391 ointments for actinic keratosis, skin cancers, and psoriasis; KX-01 oral for solid and liquid tumors; and KX2-361 for glioblastoma multiforme. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome P450 enzymes within the gastrointestinal tract; T Cell Receptor Engineered T Cell, a cell-based immunotherapy; and Pegtomarginase, an arginine deprivation therapy product. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was founded in 2003 and is headquartered in Buffalo, New York.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-21 )

Largest Industry Peers for Drug Manufacturers—Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MYL Mylan N.V

-0.95 (-6.04%)

USD8.13B 30.49 7.46
MNTA Momenta Pharmaceuticals, Inc

+0.11 (+0.21%)

USD6.22B N/A N/A
PCRX Pacira BioSciences, Inc

-1.00 (-1.65%)

USD2.60B 870.20 76.94
CRON Cronos Group Inc

-0.17 (-3.21%)

USD1.85B 2.50 N/A
IRWD Ironwood Pharmaceuticals, Inc

-0.30 (-3.00%)

USD1.60B 15.98 13.26
APHA Aphria Inc

-0.24 (-5.13%)

USD1.34B 57.50 435.71
SUPN Supernus Pharmaceuticals, Inc

-0.85 (-3.80%)

USD1.18B 10.22 6.48
AMPH Amphastar Pharmaceuticals, Inc

-0.79 (-4.01%)

USD0.93B 243.13 29.78
PETQ PetIQ, Inc

-1.14 (-3.69%)

USD0.88B 134.36 112.85
ENDP Endo International plc

-0.12 (-3.68%)

USD0.75B N/A 8.16

ETFs Containing ATNX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers—Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -18.01% 63% D 40% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -18.01% 63% D 39% F
Trailing 12 Months  
Capital Gain -12.08% 67% D+ 44% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -12.08% 67% D+ 43% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -7.95% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -7.95% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 17.50% N/A N/A N/A N/A
Risk Adjusted Return -45.42% N/A N/A N/A N/A
Market Capitalization 1.20B 90% A- 71% C-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers—Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 8.60 23% F 15% F
Price / Cash Flow Ratio -12.29 85% B 83% B
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -80.40% 52% F 16% F
Return on Invested Capital -56.42% 40% F 17% F
Return on Assets -20.67% 44% F 19% F
Debt to Equity Ratio 27.82% 46% F 57% F
Technical Ratios  
Short Ratio 22.42 5% F 2% F
Short Percent 15.17% 32% F 13% F
Beta 0.91 76% C 64% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector